coxib


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

coxib

(ˈkɒksɪb)
n
an anti-inflammatory drug
References in periodicals archive ?
Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al.
26) The Coxib and Traditional NSAID Trialists' (CNT) Collaboration identified 639 randomized trials of an NSAID vs placebo or 1 NSAID regimen vs another for analysis.
This safety announcement and the label change mandate were prompted by an FDA review of a meta-analysis of randomized controlled trials of the cardiovascular and upper gastrointestinal effects of NSAIDs conducted by the Coxib and Traditional NSAID Trialists' (CNT) Collaboration of the Clinical Trial Service and Epidemiological Studies Units at Oxford University (CNT Collaboration et al.
Bhala N, Emberson J, Merhi A, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration.
Measuring plasmatic levels of creatinine, urea, phosphorus, urinary density, aspect, color, sediment, cellularity, crystals, and proteins in urine showed no alteration; it is presumed that renal functionality was conserved, which is similar to data for other coxib, such as firocoxib, used for 90 days (18).
That new data primarily came from a study authored by the Coxib and traditional NSAID Trialists' Collaboration at Oxford (England) University (Lancet 2013:382;769-79).
Patients with chronic conditions requiring NSAIDs should receive either a coxib or concomitant therapy with misoprostol or a PPI if GI risk factors are present.
Other drugs in the coxib class include cerecoxib, sold by Pfizer under the brand name Celebrex, and etoricoxib, sold by Merck under the brand name Arcoxia.
GI bleeding risk was observed to reduce by 40 percent for coxib users, but for opioid users was similar to the risk for patients on nsNSAIDs.
12) At present, there are two primary strategies to reduce the gastrointestinal risk: use of a coxib or concurrent use of medications that protect the gut from the adverse effects of NSAIDs (gastroprotective co-therapy).
Am J Gastroenterol 2008;103:221-227) Low GI risk High GI risk * Low CV Non-selective Non-selective risk NSAID NSAID + PPI or coxib as monotherapy High Aspirin + Avoid all CV naproxen + PPI NSAIDs risk# GI=gastrointestinal, CV=cardiovascular, NSAID=non-steroidal anti-inflammatory drug, coxib=selective cyclo-oxygenase-2 inhibitor, PPI=proton pump inhibitor.